Variation Biotechnologies Inc. (VBI), also known as VBI Vaccines Inc., is a biopharmaceutical company, headquartered in Cambridge, Massachusetts, with research facilities in Ottawa, Ontario, Canada, and a research and manufacturing site in Rehovot, Israel.
[1][2] In August VBI received CA$56 million from the Government of Canada to prepare its vaccine for clinical trials by the end of 2020.
[citation needed] By 2007, VBI had received financial support from the National Research Council of Canada's Industrial Research Assistance Program, Innovation, Science and Economic Development Canada and Investissement Quebec.
[3] VBI-2901 is a "trivalent pan-coronavirus vaccine expressing the SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins".
[3] VBI received CA$56 million from the federal government towards the COVID-19 vaccine development.